Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Share-based Compensation for 8 consecutive years, with $9.4 million as the latest value for Q1 2026.

  • Quarterly Share-based Compensation rose 7.82% to $9.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38.6 million through Feb 2026, up 10.96% year-over-year, with the annual reading at $38.0 million for FY2025, 11.9% up from the prior year.
  • Share-based Compensation for Q1 2026 was $9.4 million at Nurix Therapeutics, up from $9.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $10.4 million in Q2 2025, with the low at $2.8 million in Q2 2022.
  • Average Share-based Compensation over 5 years is $8.0 million, with a median of $8.5 million recorded in 2024.
  • The sharpest move saw Share-based Compensation surged 213.89% in 2023, then fell 7.77% in 2024.
  • Over 5 years, Share-based Compensation stood at $8.3 million in 2022, then decreased by 3.29% to $8.0 million in 2023, then grew by 6.03% to $8.5 million in 2024, then grew by 6.79% to $9.1 million in 2025, then rose by 3.5% to $9.4 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $9.4 million, $9.1 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.